Clean Nuclear Med Tech With Quantum Blue Sky
Source: Penny Queen  (11/9/22)
With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention. More >

Healthcare Firm Offers US$295M for Ophthalmology Co.
Source: Streetwise Reports  (11/8/22)
Shares of Oyster Point Pharma Inc. traded 38.5% higher yesterday after the firm reported it agreed to be acquired by Viatris Inc. for US$11.00 per share along with a contingent value right for a potential additional payment of up to US$2.00 per share. More >

Pharma Co. Signs Global License Deal for Eye Drops
Source: Streetwise Reports  (11/8/22)
Shares of Ocuphire Pharma Inc. traded 20% higher after the ophthalmology-focused biopharmaceutical firm reported it executed a global license agreement with FamyGen Life Sciences Inc. to develop and commercialize its Nyxol® Eye Drops for use in treating mydriasis, presbyopia, and night vision disturbances. More >

San Diego Co. Signs US$4.2B Deal To Develop mRNA Vaccines
Source: Streetwise Reports  (11/3/22)
Arcturus Therapeutics Holdings Inc. shares traded 19% higher yesterday after the firm reported it entered a global partnership with CSL Seqirus to develop and commercialize self-amplifying mRNA vaccines worldwide. More >

Pharma Co. Earns Big Rewards from Global License Deal
Source: Streetwise Reports  (11/2/22)
Kiniksa Pharmaceuticals Ltd. shares traded 12% higher yesterday after the company reported Q3/22 financial results that included a 720% YoY increase in net revenue attributed to a combination of organic growth and increases in global licensing revenue. More >

Biopharma Co. Trades 39% Higher
Source: Streetwise Reports  (11/1/22)
Actinium Pharmaceuticals Inc. shares traded 39% higher yesterday to a new 52-week high after the firm reported topline data from its Phase 3 SIERRA study of Iomab-B in patients with active relapsed or refractory acute myeloid leukemia. During the pivotal trial, Iomab-B met its primary pre-established endpoint of durable complete remission or dCR of six months post-initial remission following a bone marrow transplant. More >

Biopharma Gains Two Cancer Cell Therapy Programs and a Target Price 10 Times Current
  (10/31/22)
This developer of cancer immunotherapies will take possession of these clinical-stage assets in a transaction with GSK and subsequently advance them toward approval, noted a ROTH Capital Partners report. More >

Biotech Co. Achieves High ORRs in Ph. 1 NSCLC Trial
Source: Streetwise Reports  (10/28/22)
Shares of Nuvalent Inc. traded 60% higher to a new 52-week intraday high after the company reported initial data from its Phase 1 ARROS-1 trial of NVL-520 demonstrating positive objective response rates in patients with ROS1-Positive non-small cell lung cancer. More >

Potential ROI With German Biopharma Co. Notable
Source: Dr. Elemer Piros  (10/27/22)
This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report. More >

Vaccine Co. Posts Positive Ph. 1/2 IPD Trial Results
Source: Streetwise Reports  (10/25/22)
Shares of Vaxcyte Inc. traded 61% higher yesterday to a new 52-week high after the company reported positive topline results from its Phase 1/2 study of VAX-24, its novel 24-valent pneumococcal conjugate vaccine candidate being developed to prevent invasive pneumococcal disease in adults 18 to 64 years of age. More >

Expert Says Buy Pharma Co. Stock 'as Soon as Possible'
Source: Clive Maund  (10/25/22)
Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy its stock. More >

Biopharma Co. Shows Large Potential Return
Source: Dr. Joseph Pantginis   (10/21/22)
Palatin Technologies Inc.'s third-party clinical trial of Vyleesi in women with hypoactive sexual desire disorder was just published in the Journal of Clinical Investigation, and the biopharma offers investors significant potential return, noted an H.C. Wainwright & Co. report. More >

Biotech Co.'s Target Price Over Three Times Current
Source: Dr. Joseph Pantginis   (10/13/22)
Expanded interim data from the Phase 2 trial of this biotech's lead asset PDS0101 in HPV16-associated cancers are consistent with previously reported results from the same study. Read more to discover why H.C Wainright & Co. believes this stock is a Buy with a target price over three times the current. More >

Biopharma Co. Partners With Merck for Combo Drug Trial
Source: Dr. Joseph Pantginis  (10/12/22)
With this and other clinical studies, the U.S. company has a busy and, thus, catalyst-rich Q4/22 ahead, noted an H.C. Wainwright & Co. report. More >

Biopharma Co.'s Shares Roll to New 52-Week High Price
Source: Streetwise Reports  (10/12/22)
Shares of DICE Therapeutics Inc. traded 62% higher yesterday and established a new 52-week intraday high after the company reported positive topline data from its Phase 1 DC-806 Psoriasis study. More >

Chen Reveals His Picks for Last Quarter
Source: Streetwise Reports  (10/11/22)
Asset manager Chen Lin's picks for the home stretch of 2022 include several biotechs and some precious metals companies. More >

US Firm Teams up With Leading Pharma Co. To Delay T1D Onset
Source: Streetwise Reports  (10/7/22)
Provention Bio Inc.'s shares traded 25% higher yesterday after the company reported it is joining forces with Sanofi U.S. to support the potential upcoming U.S. launch of its teplizumab for use in delaying the onset of clinical type 1 diabetes in at-risk patients. The U.S. FDA is expected to rule on the firm's Biologics License Application in mid-November 2022. More >

Biotech Co.'s Drug Showing 'Early Signs of Benefit'
Source: Dr. Elemer Piros  (10/6/22)
With this upcoming analysis, the board will determine whether the Phase 2b/3 trial may continue to completion, noted a ROTH Capital Partners report. More >

Trial Results of New Drug for An Eye Disease 'Encouraging'
Source: Dr. Yale Jen  (10/6/22)
The data suggest this treatment could be safer and more effective in treating proliferative vitreoretinopathy than compounded methotrexate, noted a Laidlaw & Co. report. More >

Co. Uses RNA Editing as Treatment for Rare Disease
Source: Andrew Fein  (10/3/22)
The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report. More >

Interim Results From Phase 2b Trial Are 'Encouraging'
Source: Dr. Elemer Piros  (9/30/22)
Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report. More >

Biopharma Co. Awarded FDA Clearance for Advanced Solid Tumors Trial
Source: Streetwise Reports  (9/30/22)
Shares of oncology-focused biopharmaceutical company Immuneering Corp. traded 9% higher after the firm reported it received U.S. FDA clearance for its IND Application for a Phase 1/2a clinical trial of IMM-1-104 for use in treatment of advanced solid tumors with RAS mutations. The company expects to enroll the first patient in the study in Q4/22. More >

Pharma Co. Meets Primary Endpoint in Phase 3 Alzheimer's Trial
Source: Streetwise Reports  (9/29/22)
Shares of Eisai Co. Ltd. traded 58% higher yesterday after the company reported topline data from its global Phase 3 clinical study demonstrating that its lecanemab significantly met the primary and key secondary endpoints in reducing mild cognitive impairment due to Alzheimer's disease. More >

Biopharma Asks for Emergent Use in US of New COVID Drug
Source: Edward White  (9/29/22)
The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report. More >

Oncology Co.'s Shares Erupt on Signing Global License Deal
Source: Streetwise Reports  (9/27/22)
Shares of clinical-stage immuno-oncology company LAVA Therapeutics NV traded nearly 100% higher yesterday after the firm reported that it has entered into a global licensing agreement with Seagen Inc. to advance its LAVA-1223, a preclinical gamma delta bispecific T cell engager designed for use in the treatment of EGFR-expressing solid tumors. More >